Effects of Netupitant and palonosetron hydrochloride capsules on the pharmacokinetics of albumin-bound paclitaxel in rats under different intestinal microenvironments

QIN Yuanman; CHU Wenhao; XU Jiaqi; LI Yutong; LIANG Bo; ZHANG Xueliang; LIU Jian

doi:10.6039/j.issn.1001-0408.2025.16.07

您当前的位置：

首页 >

文章列表页 >

Effects of Netupitant and palonosetron hydrochloride capsules on the pharmacokinetics of albumin-bound paclitaxel in rats under different intestinal microenvironments

更新时间：2025-09-25

- Effects of Netupitant and palonosetron hydrochloride capsules on the pharmacokinetics of albumin-bound paclitaxel in rats under different intestinal microenvironments
- ZHONGGUO YAOFANG Vol. 36, Issue 16, Pages: 1993-1999(2025)
- 作者机构：
  
  1.河北医科大学第二医院药学部，石家庄　050073
  2.河北医科大学药学院，石家庄　050011
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.16.07
  CLC： R979.1;R969.2
- Received：04 March 2025，
  
  Revised：2025-06-29，
  
  Accepted：07 July 2025，
  
  Published：30 August 2025
- 稿件说明：
移动端阅览
秦源蔓,褚文昊,许佳祺,等.不同肠道微环境下奈妥匹坦帕洛诺司琼胶囊对大鼠白蛋白紫杉醇药动学的影响[J].中国药房,2025,36(16):1993-1999.

QIN Yuanman,CHU Wenhao,XU Jiaqi,et al.Effects of Netupitant and palonosetron hydrochloride capsules on the pharmacokinetics of albumin-bound paclitaxel in rats under different intestinal microenvironments[J].ZHONGGUO YAOFANG,2025,36(16):1993-1999.
秦源蔓,褚文昊,许佳祺,等.不同肠道微环境下奈妥匹坦帕洛诺司琼胶囊对大鼠白蛋白紫杉醇药动学的影响[J].中国药房,2025,36(16):1993-1999. DOI： 10.6039/j.issn.1001-0408.2025.16.07.

QIN Yuanman,CHU Wenhao,XU Jiaqi,et al.Effects of Netupitant and palonosetron hydrochloride capsules on the pharmacokinetics of albumin-bound paclitaxel in rats under different intestinal microenvironments[J].ZHONGGUO YAOFANG,2025,36(16):1993-1999. DOI： 10.6039/j.issn.1001-0408.2025.16.07.

摘要

目的

探究不同肠道微环境下奈妥匹坦帕洛诺司琼胶囊（NEPA）对大鼠注射用紫杉醇（白蛋白结合型）（简称“白蛋白紫杉醇”）药动学的影响。

方法

将雄性SD大鼠分为正常组和模型组，每组16只。模型组大鼠灌胃万古霉素溶液构建肠道紊乱大鼠模型。造模后次日，分析其肠道菌群多样性，并检测其小肠及肝组织中细胞色素P450 3A1（CYP3A1）、CYP2C11 mRNA及肝组织中上述蛋白的表达。将雄性SD大鼠按前述方法分组，每组16只；将正常组分为TP化疗组（TP-1组）、TP化疗+NEPA组（TP+NEPA-1组），将模型组大鼠随机分为TP化疗组（TP-2组）、TP化疗+NEPA组（TP+NEPA-2组），每组8只。TP+NEPA-1组和TP+NEPA-2组大鼠分别单次灌胃NEPA混悬液25.8 mg/kg（以奈妥匹坦计）；1 h后，4组大鼠均单次尾静脉注射白蛋白紫杉醇和顺铂药液。于末次给药后的不同时间点采集血样，以阿奇霉素为内标，采用液相色谱-串联质谱法检测血浆中紫杉醇的质量浓度，并采用DAS 2.0计算其主要药动学参数并进行组间比较。

结果

与正常组大鼠相比，模型组大鼠的Chao1、Shannon指数均显著降低（

＜0.05），菌群组成及相对丰度变化明显；其肝组织中CYP3A1 mRNA、小肠及肝组织中CYP2C11 mRNA的表达均显著下调（

＜0.05）。与TP-1组比较，TP-2组大鼠体内紫杉醇的药时曲线下面积（AUC

0－

、AUC

0－∞

）、平均滞留时间（MRT

0－

），TP+NEPA-1组及TP+NEPA-2组大鼠体内紫杉醇的达峰浓度（

max

）、AUC

0－

、AUC

0－∞

均显著升高或延长；TP-2组大鼠体内紫杉醇的清除率（CL），TP+NEPA-1组及TP+NEPA-2组大鼠体内紫杉醇的表观分布容积（

）、CL均显著降低或缩短（

＜0.05）。与TP-2组比较，TP+NEPA-2组大鼠体内紫杉醇的

max

显著升高，

、MRT

0－

均显著降低或缩短（

＜0.05）。

结论

肠道菌群紊乱会影响CYP3A1、CYP2C11 mRNA的表达，导致紫杉醇在大鼠体内的清除减慢，暴露量增加；肠道菌群正常时，联用NEPA可增加紫杉醇在大鼠体内的暴露量；肠道菌群紊乱时，联用NEPA对紫杉醇体内暴露量的影响有限。

Abstract

OBJECTIVE

To investigate the impact of Netupitant and palonosetron hydrochloride capsules （NEPA） on the pharmacokinetics of Paclitaxel for injection （albumin bound）（i.e. albumin-bound paclitaxel） under different intestinal microenvironment conditions.

METHODS

Male SD rats were divided into a normal group and a model group （

＝16）. Rats in the model group were intragastrically administered vancomycin solution to establish an intestinal disorder model. The next

day after modeling， intestinal microbiota diversity was analyzed， and the mRNA expressions of cytochrome P450 3A1 （CYP3A1） and CYP2C11 in small intestine and liver tissues as well as those protein expressions in liver tissue were measured. Male SD rats were grouped as described above （

＝16）. The normal group was subdivided into the TP chemotherapy group （TP-1 group） and the TP chemotherapy+NEPA group （TP+NEPA-1 group）； the model group was subdivided into the TP chemotherapy group （TP-2 group） and the TP chemotherapy+NEPA group （TP+NEPA-2 group）（

＝8）. Rats in the TP+NEPA-1 and TP+NEPA-2 groups received a single intragastric dose of NEPA suspension （25.8 mg/kg， calculated by netupitant）. One hour later， all four groups received a single tail vein injection of albumin-bound paclitaxel and cisplatin. Blood samples were collected at different time points after the last administration. Using azithromycin as the internal standard， plasma paclitaxel concentrations were determined by liquid chromatography-tandem mass spectrometry. The main pharmacokinetic parameters were calculated using DAS 2.0 software and compared between groups.

RESULTS

Compared with the normal group， the model group showed significantly decreased Chao1 and Shannon indexes （

＜0.05）， significant alterations in microbiota composition and relative abundance， and significantly downregulated expressions of CYP3A1 mRNA in liver tissue and CYP2C11 mRNA in both small intestine and liver tissues （

＜0.05）. Compared with the TP-1 group， the AUC

0－

， AUC

0－∞

， MRT

0－

of paclitaxel in the TP-2 group， the

max

， AUC

0－

， AUC

0－∞

of paclitaxel in the TP+NEPA-1 group and TP+NEPA-2 group were significantly increased or prolonged； CL of paclitaxel in the TP-2 group，

and CL of pacli

taxel in the TP+NEPA-1 group and the TP+NEPA-2 group were significantly decreased or shortened （

＜0.05）. Compared with the TP-2 group，

max

of paclitaxel in the TP+NEPA-2 group was significantly increased， and

and MRT

0－

were significantly decreased or shortened （

＜0.05）.

CONCLUSIONS

Intestinal microbiota disorder affects the mRNA expressions of CYP3A1 and CYP2C11， leading to decreased clearance and increased systemic exposure of paclitaxel. Concomitant administration of NEPA under normal intestinal microbiota condition increases paclitaxel exposure. However， under conditions of intestinal microbiota disorder， concomitant administration of NEPA has a limited impact on paclitaxel systemic exposure.

关键词

Keywords

references

BRAY F ， LAVERSANNE M ， SUNG H ， et al . Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2024 ， 74 （ 3 ）： 229 - 263 .

VASAN N ， BASELGA J ， HYMAN D M . A view on drug resistance in cancer [J ] . Nature ， 2019 ， 575 （ 7782 ）： 299 - 309 .

陈伟，王燕婷，王宇，等 . 紫杉类抗肿瘤药物药学服务中国专家共识 [J ] . 中国医院用药评价与分析， 2022 ， 22 （ 12 ）： 1409 - 1427 .

RAPOPORT B L ， HERRSTEDT J ， SNOW R C ， et al . 2023 updated MASCC/ESMO consensus recommendations：prevention of nausea and vomiting following multiple-day chemotherapy，high-dose chemotherapy，and breakthrough nausea and vomiting [J ] . Support Care Cancer ， 2023 ， 32 （ 1 ）： 36 .

NATALE J J ， SPINELLI T ， CALCAGNILE S ， et al . Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron：review of clinical data [J ] . J Oncol Pharm Pract ， 2016 ， 22 （ 3 ）： 485 - 495 .

DEB S ， HOPEFL R . Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs [J ] . Daru ， 2023 ， 31 （ 2 ）： 95 - 105 .

DE MARTEL C ， GEORGES D ， BRAY F ， et al . Global burden of cancer attributable to infections in 2018：a worldwide incidence analysis [J ] . Lancet Glob Health ， 2020 ， 8 （ 2 ）： e180 - e190 .

LI X C ， GUO X L ， LIU Y X ， et al . Antibiotics affect the pharmacokinetics of n-butylphthalide in vivo by altering the intestinal microbiota [J ] . PLoS One ， 2024 ， 19 （ 6 ）： e0297713 .

ZIMMERMANN M ， ZIMMERMANN-KOGADEEVA M ， WEGMANN R ， et al . Mapping human microbiome drug metabolism by gut bacteria and their genes [J ] . Nature ， 2019 ， 570 （ 7762 ）： 462 - 467 .

WALSH J ， GHEORGHE C E ， LYTE J M ， et al . Gut microbiome-mediated modulation of hepatic cytochrome P450 and P-glycoprotein：impact of butyrate and fructo-oligosaccharide-inulin [J ] . J Pharm Pharmacol ， 2020 ， 72 （ 8 ）： 1072 - 1081 .

HUANG C ， FENG S Y ， HUO F J ， et al . Effects of four antibiotics on the diversity of the intestinal microbiota [J ] . Microbiol Spectr ， 2022 ， 10 （ 2 ）： e0190421 .

陈怡琴，杨娇，裴文丽，等 . 黑逍遥散对APP/PS1小鼠认知障碍及其肠道菌群的调节作用 [J/OL ] . 中国实验方剂学杂志， 2025 ： 1 - 18 [ 2025-06-11 ] . https：//link.cnki.net/doi/10.13422/j.cnki.syfjx.20250905 https://link.cnki.net/doi/10.13422/j.cnki.syfjx.20250905 .

MANHAS D ， BHATT S ， RAI G ， et al . Rottlerin renders a selective and highly potent CYP2C8 inhibition to impede EET formation for implication in cancer therapy [J ] . Chem Biol Interact ， 2023 ， 380 ： 110524 .

中国抗癌协会癌症康复与姑息治疗专业委员会，中国抗癌协会肿瘤临床化疗专业委员会，中国抗癌协会肿瘤支持治疗专业委员会，等 . 中国抗肿瘤治疗相关恶心呕吐预防和治疗指南： 2023版 [J ] . 中华肿瘤杂志， 2024 ， 46 （ 6 ）： 481 - 501 .

钱隽，郁韵秋 . 液相色谱-质谱联用分析紫杉醇和多西他赛中流动相体系的优化 [J ] . 复旦学报（医学版）， 2012 ， 39 （ 6 ）： 605 - 610 .

HAAK B W ， LANKELMA J M ， HUGENHOLTZ F ， et al . Long-term impact of oral vancomycin，ciprofloxacin and metronidazole on the gut microbiota in healthy humans [J ] . J Antimicrob Chemother ， 2019 ， 74 （ 3 ）： 782 - 786 .

GUO J ， XU Y ， CHEN L J ， et al . Gut microbiota and host CYP450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis：effects vary from drug to drug [J ] . J Adv Res ， 2022 ， 39 ： 319 - 332 .

TOGAO M ， KAWAKAMI K ， OTSUKA J ， et al . Effects of gut microbiota on in vivo metabolism and tissue accumulation of cytochrome P450 3A metabolized drug：midazolam [J ] . Biopharm Drug Dispos ， 2020 ， 41 （ 7 ）： 275 - 282 .

FLOWERS S A ， BHAT S ， LEE J C . Potential implications of gut microbiota in drug pharmacokinetics and bioavai-lability [J ] . Pharmacotherapy ， 2020 ， 40 （ 7 ）： 704 - 712 .

AVIOR Y ， LEVY G ， ZIMERMAN M ， et al . Microbial-derived lithocholic acid and vitamin K2 drive the metabolic maturation of pluripotent stem cells-derived and fetal hepatocytes [J ] . Hepatology ， 2015 ， 62 （ 1 ）： 265 - 278 .

ISHII M ， TODA T ， IKARASHI N ， et al . Gastrectomy increases the expression of hepatic cytochrome P450 3A by increasing lithocholic acid-producing enteric bacteria in mice [J ] . Biol Pharm Bull ， 2014 ， 37 （ 2 ）： 298 - 305 .

WIKOFF W R ， ANFORA A T ， LIU J ， et al . Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites [J ] . Proc Natl Acad Sci USA ， 2009 ， 106 （ 10 ）： 3698 - 3703 .

MUN S J ， LEE J ， CHUNG K S ， et al . Effect of microbial short-chain fatty acids on CYP3A4-mediated metabolic activation of human pluripotent stem cell-derived liver organoids [J ] . Cells ， 2021 ， 10 （ 1 ）： 126 .

BILEN M ， DUFOUR J C ， LAGIER J C ， et al . The contribution of culturomics to the repertoire of isolated human bacterial and archaeal species [J ] . Microbiome ， 2018 ， 6 （ 1 ）： 94 .

NATIVIDAD J M ， AGUS A ， PLANCHAIS J ， et al . Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome [J ] . Cell Metab ， 2018 ， 28 （ 5 ）： 737 - 749.e4 .

ZHANG X T ， HAN Y ， HUANG W ， et al . The influence of the gut microbiota on the bioavailability of oral drugs [J ] . Acta Pharm Sin B ， 2021 ， 11 （ 7 ）： 1789 - 1812 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of Compound troxerutin and poreine cerebroside injection on cytochrome P450 enzyme in vivo and in vitro

国产与进口他汀类药说明书在药物相互作用方面的差异

心血管类中成药代谢性药物相互作用的研究进展

10种心血管类中药注射剂对人细胞色素P4507种亚型的体外抑制作用

临床药师对1例慢性肾功能不全合并心房血栓患者抗凝治疗的药学监护

Related Author

LI Ziqiang

LIU Fanqi

WANG Baohe

HUANG Yuhong

LI Nan

WANG Jingyuan

徐静郎奕

刘丽雅韩永龙杨全军郭澄

Related Institution

Graduate School， Tianjin University of Traditional Chinese Medicine

Clinical Pharmacology Center， the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Center for Traditional Chinese Medicine， the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰